EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Integrative Systematic Review on Pharmacological, Psychotherapeutic, and Neurostimulatory Treatment Options in Treatment-Resistant Anxiety Disorders

Miriam A Schiele, Harry A Fagan, David S Baldwin, Katharina Domschke

Psychotherapy and Psychosomatics · 14.09.2025 · 95 (3) · 214-247

DOI: 10.1159/000547926 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Psychotherapy and Psychosomatics, online erschienen am 14.09.2025. Verfasst von Miriam A Schiele und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Anti-Anxiety Agents, Generalized Anxiety Disorder, Psychotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Treatment resistance in anxiety disorders (TR-ADs) constitutes a major clinical challenge conferring a considerable burden regarding quality of life and societal health costs.

Methods

This systematic review provides an overview of pharmacological, psychotherapeutic, and neurostimulatory treatment options in adults with treatment-resistant generalized anxiety disorder (TR-GAD), panic disorder (TR-PD)/agoraphobia, and social anxiety disorder (TR-SAD).

Results

A total of 26 randomized controlled trials (RCTs) and 36 open label studies were identified, with, however, mostly small sample sizes and several methodological limitations. According to RCTs, selective serotonin reuptake inhibitors (SSRIs) or clomipramine are effective in TR-PD after failure to respond to cognitive behavioral therapy (CBT). In pharmacological TR-SAD, switching from one SSRI to another or to venlafaxine was found helpful in open label trials. RCTs further suggest augmentation with quetiapine, risperidone, olanzapine, or pregabalin in TR-GAD, pindolol in TR-PD, and clonazepam in TR-SAD. Open label studies in TR-AD provide preliminary evidence for ketamine or augmentation with nefazodone, reboxetine, buspirone, aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone, divalproex sodium, levetiracetam, zonisamide, flumazenil, pregabalin, cannabidiol, and acamprosate. For pharmacological TR, CBT was effective in several RCTs. Following nonresponse to CBT, first evidence suggests effectiveness of Acceptance and Commitment Therapy and Mindfulness-Based Cognitive Therapy. Only inconclusive support was identified for repetitive transcranial magnetic stimulation in TR-AD.

Conclusion

In summary, this integrative review may provide an evidence base for expert recommendations, inform clinical guidelines, and inspire further research into innovative, personalized treatment of TR-AD increasing response rates and lowering the considerable individual and public health burden of anxiety disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Anxiety AgentsGeneralized Anxiety DisorderPsychotherapyHumansCognitive Behavioral TherapyPhobia, SocialSelective Serotonin Reuptake Inhibitors

Stichwörter der Autor:innen

Evidence-based careNonresponseTreatment resistanceTreatment-refractory

Substanzen

Anti-Anxiety AgentsSelective Serotonin Reuptake Inhibitors

Autor:innen und Institutionen

  • Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
  • Hampshire and Isle of Wight Healthcare NHS Foundation Trust, Southampton, UK.
  • South African Medical Research Council Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Neuroscience Institute, University of Cape Town, Cape Town, South Africa.
  • Department of Psychiatry and Psychotherapy, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, katharina.domschke@uniklinik-freiburg.de.
  • German Center for Mental Health (DZPG), Partner Site Berlin/Potsdam, Berlin, Germany, katharina.domschke@uniklinik-freiburg.de.

Zitieren

APA

Schiele, M. A., Fagan, H. A., Baldwin, D. S., & Domschke, K. (2025). Integrative Systematic Review on Pharmacological, Psychotherapeutic, and Neurostimulatory Treatment Options in Treatment-Resistant Anxiety Disorders. Psychotherapy and Psychosomatics, 95(3), 214-247. https://doi.org/10.1159/000547926

Vancouver

Schiele MA, Fagan HA, Baldwin DS, Domschke K. Integrative Systematic Review on Pharmacological, Psychotherapeutic, and Neurostimulatory Treatment Options in Treatment-Resistant Anxiety Disorders. Psychotherapy and Psychosomatics. 2025;95(3):214-247. doi:10.1159/000547926

BibTeX
@article{Schiele2025,
  author = {Schiele, Miriam A and Fagan, Harry A and Baldwin, David S and Domschke, Katharina},
  title = {Integrative Systematic Review on Pharmacological, Psychotherapeutic, and Neurostimulatory Treatment Options in Treatment-Resistant Anxiety Disorders},
  journal = {Psychotherapy and Psychosomatics},
  year = {2025},
  volume = {95},
  number = {3},
  pages = {214--247},
  doi = {10.1159/000547926}
}
Kostenlos starten →